Assembly Biosciences (ASMB) AI Stock Analysis

• Market Cap: $138.55M
• Dividend Yield: N/A
• Average Volume (3M): 32.15K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.29
• Revenue Growth: 148.33%
• EPS Growth: 42.41%
• Country: US
• Employees: 73
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -1.17
• Shares Outstanding: 7,637,553
• 10 Day Avg. Volume: 54,887
• 30 Day Avg. Volume: 32,145
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.76
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.74
• Enterprise Value/Market Cap: 0.10
• Enterprise Value/Revenue: 0.13
• Enterprise Value/Gross Profit: 0.44
• Enterprise Value/Ebitda: -0.08
• 1Y Price Target: $30.00
• Price Target Upside: 65.38% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 62 Neutral
• Price Target: $18.50 ▲(1.98%Upside)

The overall stock score is driven by strong technical momentum and positive corporate developments from the recent trial results. However, significant financial challenges and negative valuation metrics weigh heavily on the score, reflecting underlying risks.

Positive Factors

Financial Investment

Gilead's latest equity investment, priced at a premium, raises Gilead's ownership of outstanding ASMB voting stock from approximately 19.9% to 29.9%.

Positive Drug Profile

ABI-5366's PK profile is supportive of once-weekly or once-monthly dosing, which is highly encouraging.

Potential Market Opportunity

ABI-6250's oral bioavailability is a key attribute, indicating the potential for once-daily oral dosing, possibly becoming the first oral chronic HDV treatment.

Negative Factors

Efficacy Uncertainty

There is current uncertainty on the efficacy of Assembly's programs including ABI-5366, ABI-4334, and ABI-6250, at a level that could potentially support their advancement towards regulatory approvals.

Operational Risks

Key risks include failed or equivocal trial results, unforeseen safety or tolerability issues, meaningful delays to expected timelines, and inability to sufficiently fund operations.

Timeline Delays

Data readout for ABI-5366, originally expected in the first half of 2025, has been delayed to Fall 2025.

Assembly Biosciences Business Overview & Revenue Model

Company Description

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

How the Company Makes Money

Assembly Biosciences generates revenue primarily through strategic partnerships, collaborations, and licensing agreements with other pharmaceutical companies. These partnerships often involve upfront payments, milestone payments based on the achievement of certain clinical, regulatory, or sales objectives, and royalties on potential future sales of any successfully developed products. Additionally, the company may engage in research and development collaborations that provide funding to support its proprietary drug development programs. However, as a company heavily focused on R&D, Assembly Biosciences may still be in the phases of clinical trials and not yet generating significant revenue from product sales.

Assembly Biosciences Financial Statement Overview

Summary

Assembly Biosciences exhibits financial distress across key areas. The absence of revenue in recent years, combined with enduring net losses and negative cash flows, suggests significant profitability and liquidity challenges. While leverage remains low, declining equity and assets reflect potential financial instability, requiring strategic reassessment.

Income Statement

Assembly Biosciences has faced significant challenges with consistent revenue declines from $79.1M in 2020 to $0 in 2022 and 2024, indicating potential instability. The company has struggled with persistent net losses and negative profit margins, including a net profit margin of -100% in 2024. These factors highlight major profitability issues.

Balance Sheet

While the company maintains a reasonable equity ratio of 28% in 2024, indicative of some financial stability, the declining stockholders' equity from $240.6M in 2020 to $33.4M in 2024 raises concerns. A relatively low debt-to-equity ratio of 0.09 in 2024 suggests manageable leverage, but the shrinking equity indicates potential risk.

Cash Flow

Assembly Biosciences experiences significant volatility in free cash flow, with figures dropping sharply from $22.5M in 2023 to -$51.1M in 2024. The negative operating cash flow and free cash flow pose risks to future liquidity and financial health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	32.15M	28.52M	7.16M	0.00	6.25M	79.11M
Gross Profit	32.09M	28.39M	-41.74M	-498.00K	5.79M	79.00M
EBITDA	-44.50M	-45.42M	-64.20M	-92.59M	-91.93M	-64.78M
Net Income	-39.92M	-40.18M	-61.23M	-92.07M	-129.85M	-59.53M
Balance Sheet
Total Assets	99.02M	119.17M	136.82M	101.79M	191.06M	283.25M
Cash, Cash Equivalents and Short-Term Investments	91.03M	112.08M	130.25M	91.61M	146.63M	216.41M
Total Debt	3.02M	3.09M	2.34M	3.46M	6.48M	10.13M
Total Liabilities	71.88M	85.81M	95.73M	19.13M	22.13M	42.68M
Stockholders Equity	27.13M	33.36M	41.10M	82.66M	168.93M	240.58M
Cash Flow
Free Cash Flow	-56.21M	-51.15M	22.49M	-84.56M	-96.49M	-65.18M
Operating Cash Flow	-56.19M	-51.12M	22.74M	-84.46M	-93.40M	-62.96M
Investing Cash Flow	29.48M	40.17M	-69.14M	90.64M	26.52M	68.07M
Financing Cash Flow	31.37M	29.45M	13.82M	614.00K	53.06M	7.60M

Assembly Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 18.14
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ASMB, the sentiment is Positive. The current price of 18.14 is above the 20-day moving average (MA) of 17.18, above the 50-day MA of 14.64, and above the 200-day MA of 14.36, indicating a bullish trend. The MACD of 0.96 indicates Positive momentum. The RSI at 68.18 is Neutral, neither overbought nor oversold. The STOCH value of 62.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ASMB.

Assembly Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ASMB	62 Neutral	$138.55M	―	-133.65%	―	148.33%	42.41%
Sector *	52 Neutral	$7.53B	0.32	-61.76%	2.28%	16.60%	1.56%
MNOV		$61.31M	―	-20.33%	―	―	―
VTYX	41 Neutral	$148.02M	―	-46.04%	―	―	39.58%
ABOS	36 Underperform	$70.27M	―	-55.68%	―	―	-57.45%
RANI	32 Underperform	$33.85M	―	-1372.59%	―	―	20.85%
GNTA		$69.50M	―	-54.30%	―	―	―

Assembly Biosciences Corporate Events

Assembly Biosciences Reports Positive Phase 1b Trial Results

On June 25, 2025, Assembly Biosciences announced positive topline results from a Phase 1b clinical trial evaluating ABI-4334, a next-generation capsid assembly modulator, in participants with chronic hepatitis B virus infection. The trial demonstrated favorable safety, tolerability, and pharmacokinetics, supporting once-daily oral dosing. The results showed significant antiviral activity, with mean plasma HBV DNA reductions consistent across different dosage cohorts. These findings support the potential of ABI-4334 to inhibit viral replication and cccDNA formation, crucial for HBV treatment regimens. The completion of the trial triggers an opt-in point for collaboration with Gilead Sciences, Inc., which could impact future development and commercialization efforts.

The most recent analyst rating on (ASMB) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Assembly Biosciences stock, see the ASMB Stock Forecast page.

Assembly Biosciences Announces Stock Plan Amendments and Leadership Change

At the Annual Meeting of Stockholders on June 5, 2025, Assembly Biosciences, Inc. announced the approval of amendments to its 2018 Stock Incentive Plan and Employee Stock Purchase Plan, increasing the number of shares reserved for issuance. These amendments aim to enhance the company’s retention grant program and support employee stock purchases, reflecting a strategic move to bolster employee engagement and retention. Additionally, Jeanette M. Bjorkquist was appointed as the principal financial officer, succeeding Jason A. Okazaki, who remains the principal executive officer. This management change signifies a continued focus on strengthening the company’s financial leadership.

The most recent analyst rating on (ASMB) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Assembly Biosciences stock, see the ASMB Stock Forecast page.